알테오젠의 파트너사 MSD는 'Keytruda'와 'Keytruda Qlex'가 수술전후 근육 침투성 방광암(muscle-invasive bladder canc…
Merck.com
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisp…
Represents the first PD-1 inhibitor plus ADC regimens for this patient population Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and b…
